Media stories about Antares Pharma (NASDAQ:ATRS) have trended positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Antares Pharma earned a coverage optimism score of 0.34 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 45.3956951231606 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment’s rankings:

A number of equities analysts have issued reports on ATRS shares. HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Antares Pharma in a report on Thursday, February 15th. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $3.94.

Antares Pharma (NASDAQ ATRS) opened at $2.19 on Friday. The stock has a market capitalization of $343.12, a P/E ratio of -19.91 and a beta of 0.23. Antares Pharma has a twelve month low of $1.58 and a twelve month high of $4.09. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 0.69.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with's FREE daily email newsletter.